Are Your Patients with COVID-19 Eligible for Monoclonal Antibody Treatment

February 26, 2021

Patients who test positive for COVID-19 may qualify to receive monoclonal antibody treatment (casirivimab and imdevimab).

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for these medications last November for mild or moderate cases of COVID-19 in adults and children who are at high risk with at least one health condition.

In a clinical trial of patients with COVID-19, monoclonal antibody treatment reduced hospitalization or emergency room visits in high risk patients. The safety and effectiveness of this treatment for COVID-19 continues to be evaluated.

The U.S. Department of Health and Human Services offers a resource to help patients find locations for monoclonal antibody treatment: Therapeutics Distribution Locations.

For more information, download the Illinois Department of Public Health’s InfoSheet

If you have questions, please contact the ISMS Health Policy Research and Advocacy team by email

Share this article:

Cookie Consent

Cookies are required for some functionality on our site. View our privacy policy for more information.